Lead Product(s) : 212-Pb NG001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : F-Prime Capital
Deal Size : $23.0 million
Deal Type : Financing
Details : The financing enables ARTBIO's ongoing clinical development of its lead program AB001 (212Pb-NG001) for the treatment of prostate cancer and will advance its AlphaDirect™ Pb212 isolation technology.
Product Name : AB001
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
June 21, 2023
Lead Product(s) : 212-Pb NG001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : F-Prime Capital
Deal Size : $23.0 million
Deal Type : Financing
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : IOVaxis Therapeutics
Deal Size : $3.0 million
Deal Type : Licensing Agreement
Details : Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore...
Product Name : TG01
Product Type : Vaccine
Upfront Cash : Undisclosed
June 01, 2021
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : IOVaxis Therapeutics
Deal Size : $3.0 million
Deal Type : Licensing Agreement